imatinib mesylate has been researched along with Anemia, Fanconi in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheong, SK; Leong, CF; Norziha, ZA; Simbun, A; Tumian, NR; Wong, CL; Yap, E | 1 |
| Bakhanashvili, M; Beery, E; Birenbaum, M; Fenig, E; Lahav, M; Luria, D; Nordenberg, J; Reshef, H; Sandbank, J; Uziel, O; Yerushalmi, R | 1 |
2 other study(ies) available for imatinib mesylate and Anemia, Fanconi
| Article | Year |
|---|---|
MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Topics: Adult; BRCA1 Protein; Case-Control Studies; Computer Simulation; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Fanconi Anemia; Fusion Proteins, bcr-abl; Gene Expression Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Middle Aged | 2017 |
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Fanconi Anemia; Humans; Imatinib Mesylate; Melanoma; Mice; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Ewing; Skin Neoplasms; Telomerase; Tumor Cells, Cultured | 2005 |